Nektar Therapeutics Stock Forecast

Stock Price Forecast

According to 12 analysts polled by S&P Global, Nektar Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $144.4. The average 1-year stock price forecast is 101.25% higher than the current stock price, while the lowest is $65 (-9.41%) and the highest is $192 (+167.60%).

Price Target: $144.4 (+101.25%)

Analyst Consensus: Strong Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$65	$144.4	$150.5	$192
Change	-9.41%	+101.25%	+109.76%	+167.60%

Analyst Ratings

The average analyst rating for Nektar Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart

Rating	Mar '26	Apr '26	May '26	Jun '26	Jul '26	Aug '26
Strong Buy	8	8	8	8	9	9
Buy	1	1	1	1	1	1
Hold	1	1	1	1	1	2
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	10	10	10	10	11	12

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Jessica Fye J.P. Morgan	J.P. Morgan	Hold Initiates $65	Hold	Initiates	$65	-9.41%	Aug 21, 2026
Yasmeen Rahimi Piper Sandler	Piper Sandler	Buy Maintains $192	Buy	Maintains	$192	+167.60%	Aug 20, 2026
Edward Nash Canaccord Genuity	Canaccord Genuity	Buy Reiterates $153	Buy	Reiterates	$153	+113.24%	Aug 17, 2026
Arthur He CFA H.C. Wainwright	H.C. Wainwright	Buy Maintains $185	Buy	Maintains	$185	+157.84%	Aug 17, 2026
Martin Fan Wedbush	Wedbush	Hold Maintains $80	Hold	Maintains	$80	+11.50%	Aug 14, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

41.88M

from 55.23M

-24.18%

from 55.23M

Revenue Next Year

57.00M

from 41.88M

36.10%

from 41.88M

EPS This Year

-8.47

from -8.66

EPS Next Year

-10.84

from -8.47

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	101.91M	92.06M	90.12M	98.43M	55.23M	41.88M
Revenue Growth	-33.36%	-9.67%	-2.10%	9.22%	-43.89%	-24.18%
Gross Profit	77.01M	70.42M	56.35M	67.74M	55.23M	41.88M
Gross Margin	75.57%	76.50%	62.53%	68.82%	100.00%	100.00%
Operating Income	-446.10M	-240.24M	-135.23M	-129.92M	-130.77M	-241.69M
Net Income	-523.84M	-368.20M	-276.06M	-118.96M	-164.08M	-248.67M
EPS	-	-	-	-	-8.66	-8.47
Free Cash Flow	-234.18M	-101.13M	-63.63M	-43.69M	-108.23M	-234.40M
No. Analysts	-	-	-	-	-	12

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	45.0M
Avg	41.9M
Low	41.0M

Revenue Growth

Chart

Revenue Growth	2026	2027	2028
High	-18.5%
Avg	-24.2%
Low	-25.9%

EPS Forecast

Chart

EPS	2026	2027	2028
High	-7.52
Avg	-8.47
Low	-9.63

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-